Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851

Published: 2025-03-28 07:49:56 ET LXRX

March 28 (Reuters) - Lexicon Pharmaceuticals Inc :

* LEXICON PHARMACEUTICALS ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH NOVO NORDISK FOR LX9851

* LEXICON PHARMACEUTICALS INC - ELIGIBLE FOR UP TO $75 MILLION IN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS

* LEXICON PHARMACEUTICALS INC - ELIGIBLE FOR $1 BILLION IN TOTAL PAYMENTS

* LEXICON PHARMACEUTICALS INC - ENTITLED TO TIERED ROYALTIES ON NET SALES OF LX9851

* LEXICON - NOVO NORDISK WILL BE RESPONSIBLE FOR FILING IND, ALL FURTHER DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF LX9851 Source text: Further company coverage: